Smoke Free Sweden: Oral Nicotine Pouches Are Game-changer for Women in Sweden's Smoke-free Success
Article content
STRASBOURG, France — New research from Smoke Free Sweden reveals oral nicotine pouches are a game-changer in Sweden's path to becoming the world's first smoke-free nation – and are driving unprecedented success among women.
Article content
The report, Power in a Pouch
Article content
, launched today in Strasbourg, shows pouches have been a decisive catalyst in Sweden's public health success – especially for women, who are quitting smoking faster and more effectively than ever.
Article content
Since their introduction in 2016, tobacco-free pouches have:
Article content
Helped to accelerate the decline in smoking for both genders, with a nearly 200% rise in quit rates among women.
Outperformed all other quit aids; women ranked pouches nearly three times higher than vapes and 56% higher than gum.
Been identified by the research as the preferred quit aid for all ex-smokers for being clean, socially considerate and stigma-free.
Driven a 49% drop in smoking among women, who historically quit at lower rates than men.
Article content
'The evidence is crystal clear: nicotine pouches are the most effective way to help smokers – especially women – quit,' said report co-author Dr. Marewa Glover, a behavioural scientist from New Zealand.
Article content
'Health data and women's testimonials show pouches are safe, socially acceptable, and fit modern lifestyles. They're pragmatic, effective, and our best hope for a smoke-free future.'
Article content
Sweden's harm reduction strategy stands in contrast to restrictive approaches elsewhere. Rather than banning safer products, Sweden embraced them – recognising they are far less harmful than cigarettes.
Article content
Sweden's smoking rate is now 5.3%, just above the 5% smoke-free benchmark. Male lung cancer deaths are 61% below the EU average; total cancer deaths, 34% lower.
Article content
Report co-author Dr. Delon Human warned that excessive regulation could jeopardise these gains, especially for women.
Article content
'Misguided bans are blocking access to products that save lives,' said Dr. Human, leader of Smoke Free Sweden and former Secretary-General of the World Medical Association.
Article content
'That's not just bad policy – it's a public health disaster. Women deserve access to the quit aid that works best.'
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Marking Scleroderma Awareness Month
Atlantic Watch A woman recently diagnosed with scleroderma shares what she wishes people would know about the autoimmune disease.
National Post
5 hours ago
- National Post
Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)
Article content BARCELONA, Spain — Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease 1. Article content We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to advancing this promising therapy to patients. Article content 'We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to advancing this promising therapy as quickly as possible to benefit as many patients as possible,' said Mario Rovirosa, Chief Executive Officer of Ferrer. Article content Fast Track designation is a significant milestone in the drug development process. It is a program that offers the possibility of having more frequent meetings with the FDA to discuss the drug's development, eligibility for Accelerated Approval and Priority Review if relevant criteria are met. Article content 'This designation underscores the importance of expediting the development and review of FNP-223 to address critical unmet needs in patients with this rare and devastating disease,' said Marta Parmar, Ferrer's Chief Quality, Regulatory and Pharmacovigilance Officer. Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems 2-4. PSP has a prevalence of approximately 5 cases per 100,000 people and primarily affects individuals over the age of 60 3. The disease's etiology is believed to be related to the abnormal accumulation of tau proteins in certain areas of the brain, leading to neurodegeneration 3,4. Preclinical models have demonstrated that FNP-223 can prevent the abnormal accumulation of tau proteins in neurons 5. Ferrer now aims to show that this molecule is safe and effective in patients with PSP. Article content Oscar Pérez Article content , Chief Scientific Officer of Ferrer, also expressed his enthusiasm: 'Receiving Fast Track designation is a significant milestone in our journey to provide a transformative treatment for PSP. We are excited to advance our research and hopefully offer a new therapeutic option earlier for patients living with this challenging condition.' Article content About FNP-223 Article content FNP-223 is a new orally administered chemical compound that functions as a reversible and substrate-competitive inhibitor of the O-GlcNAcase (OGA) enzyme 5. Mechanistically, FNP-223 binds to the active site of OGA enzyme. As a result, the inhibitor prevents the substrate from accessing the catalytic pocket, thereby impeding the removal of O-GlcNAc modifications from natural client proteins such as the tau protein. Inhibiting O-GlcNAcase is expected to cause a rapid increase of O-GlcNAcylated (glycosylated) tau proteins, ultimately leading to a reduction in abnormal aggregated tau as neurofibrillary tangles (NFT) over a certain period 5. Article content Bibliography: Article content 1. A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER). [Internet]. Available from: Article content 2. Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord. 2020 Apr;73:105-116. doi: 10.1016/ Epub 2020 May 25. Article content 3. Agarwal S, Gilbert R. Progressive Supranuclear Palsy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: Article content 4. Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021;21(5):376-383. doi: 10.1136/practneurol-2020-002794. Article content 5. Permanne B, Sand A, Ousson S, Nény M, Hantson J, Schubert R, et al. D. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022 Apr 20;13(8):1296-1314. doi: 10.1021/acschemneuro.2c00057. Article content Article content Article content Article content Article content
National Post
7 hours ago
- National Post
Smoke Free Sweden: Oral Nicotine Pouches Are Game-changer for Women in Sweden's Smoke-free Success
Article content STRASBOURG, France — New research from Smoke Free Sweden reveals oral nicotine pouches are a game-changer in Sweden's path to becoming the world's first smoke-free nation – and are driving unprecedented success among women. Article content The report, Power in a Pouch Article content , launched today in Strasbourg, shows pouches have been a decisive catalyst in Sweden's public health success – especially for women, who are quitting smoking faster and more effectively than ever. Article content Since their introduction in 2016, tobacco-free pouches have: Article content Helped to accelerate the decline in smoking for both genders, with a nearly 200% rise in quit rates among women. Outperformed all other quit aids; women ranked pouches nearly three times higher than vapes and 56% higher than gum. Been identified by the research as the preferred quit aid for all ex-smokers for being clean, socially considerate and stigma-free. Driven a 49% drop in smoking among women, who historically quit at lower rates than men. Article content 'The evidence is crystal clear: nicotine pouches are the most effective way to help smokers – especially women – quit,' said report co-author Dr. Marewa Glover, a behavioural scientist from New Zealand. Article content 'Health data and women's testimonials show pouches are safe, socially acceptable, and fit modern lifestyles. They're pragmatic, effective, and our best hope for a smoke-free future.' Article content Sweden's harm reduction strategy stands in contrast to restrictive approaches elsewhere. Rather than banning safer products, Sweden embraced them – recognising they are far less harmful than cigarettes. Article content Sweden's smoking rate is now 5.3%, just above the 5% smoke-free benchmark. Male lung cancer deaths are 61% below the EU average; total cancer deaths, 34% lower. Article content Report co-author Dr. Delon Human warned that excessive regulation could jeopardise these gains, especially for women. Article content 'Misguided bans are blocking access to products that save lives,' said Dr. Human, leader of Smoke Free Sweden and former Secretary-General of the World Medical Association. Article content 'That's not just bad policy – it's a public health disaster. Women deserve access to the quit aid that works best.' Article content Article content Article content Article content Article content Article content
